Loading…
Unmet Needs and the Path Forward in Joint Disease Associated with Calcium Pyrophosphate Crystal Deposition
Calcium pyrophosphate (CPP) crystal deposition (CPPD) is prevalent, and can be associated with synovitis and joint damage. The older-aged population predominantly affected by CPPD is growing rapidly. Since shortfalls exist in many aspects of CPPD, we conducted an anonymous survey of CPPD unmet needs...
Saved in:
Published in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2018-08, Vol.70 (8), p.1182-1191 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Calcium pyrophosphate (CPP) crystal deposition (CPPD) is prevalent, and can be associated with synovitis and joint damage. The older-aged population predominantly affected by CPPD is growing rapidly. Since shortfalls exist in many aspects of CPPD, we conducted an anonymous survey of CPPD unmet needs, prioritized by experts from the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). We provide our perspectives on the survey results, and propose several CPPD basic and clinical translational research pathways. Chondrocyte and cartilage culture systems for generating CPP crystals
in vitro
, and transgenic small animal CPPD models are needed to better define CPPD mechanism paradigms and help guide new therapies. CPPD recognition, clinical research, and care would be improved by international consensus on CPPD nomenclature and disease phenotype classification, better exploitation of advanced imaging, and pragmatic new point-of-care crystal analytic approaches for detecting CPP crystals. Clinical impact of CPP crystals in OA, and in asymptomatic joints in the aged, remain major unanswered questions, rendered more difficult by current inability to therapeutically limit or dissolve the crystal deposits and assess consequent clinical outcome. Going forward, CPPD clinical research studies should define clinical settings in which articular CPPD does substantial harm, and include analyses of diverse clinical phenotypes and populations. Clinical trials should identify the best therapeutic targets to limit CPP crystal deposition and associated inflammation, and include assessment of intra-articular agents. Our perspective is that such advances in basic and clinical science in CPPD are now within reach, and can lead to better treatments for this disorder. |
---|---|
ISSN: | 2326-5191 2326-5205 |
DOI: | 10.1002/art.40517 |